Savara ApS

Address: Amaliegade 10

Sponsor Overview

assignment

Specializations

Autoimmune Pulmonary Alveolar Proteinosis

Savara ApS focuses on clinical research in autoimmune pulmonary alveolar proteinosis, a rare interstitial lung disease marked by impaired clearance of surfactant within the lungs. The sponsor's studies are centered on respiratory disease management and the needs of patients affected by this uncommon pulmonary disorder.

Autoimmune pulmonary alveolar proteinosis
Rare lung disease
Surfactant accumulation

Its research activity includes both adult and pediatric populations, reflecting interest in age-specific manifestations of the same underlying pulmonary condition.

Respiratory Therapeutics

The sponsor's trial portfolio is concentrated in inhaled therapy for respiratory medicine, with attention to treatments designed for direct delivery to the lungs. This includes work on molgramostim as an investigational approach in patients with aPAP.

Inhaled therapy
Respiratory medicine
Molgramostim

The clinical focus is on lung-targeted treatment for a rare inflammatory and surfactant-related disorder.

Pediatric Pulmonology

Savara ApS is also active in pediatric pulmonology, with research directed toward children and adolescents living with autoimmune pulmonary alveolar proteinosis. This area addresses the clinical features and treatment considerations of a rare lung disease in younger patients.

Pediatric patients
Adolescent respiratory disease
Rare pediatric lung disorders

Its work extends the therapeutic interest in inhaled molgramostim to a younger age group with limited treatment options.

Trial Name	Country	Status
Efficacy and Safety Evaluation of Inhaled Molgramostim in Pediatric Patients with Autoimmune Pulmonary Alveolar Proteinosis	Germany	Recruiting
Randomized, Double-Blind, Placebo-Controlled Trial of Inhaled Molgramostim in Adults with Autoimmune Pulmonary Alveolar Proteinosis	Belgium France Germany Ireland Italy Poland Portugal Romania Spain	Not Recruiting